REGISTER
Hengrui’s Homegrown Basal Insulin Wins Approval in China, Anchoring a Metabolic Pivot
Hengrui Pharmaceuticals has secured Chinese approval for shudi insulin, described by the company as the first domestically developed long-acting basal insulin analog. Two Phase 3 trials in type 2 diabetes reported HbA1c reductions comparable to insulin glargine and lower hypoglycemia. The approval signals Hengrui’s expansion beyond oncology and serves as the regulatory bridge for HR17031, an insulin/GLP-1 fixed-dose combination now under NMPA review.

Hengrui Pharmaceuticals said in late July that China’s National Medical Products Administration (NMPA) has approved shudi insulin, the company’s once-daily basal insulin analog, in what the firm describes as the first domestically developed long-acting insulin to reach the Chinese market.

A Strategic Pivot Beyond Oncology

The approval caps more than a decade of investment in chronic-disease therapeutics at Hengrui, a Jiangsu-based company best known for oncology drugs including PD-1 inhibitors and antibody-drug conjugates. According to its 2025 annual report, Hengrui reported total revenue of 31.629 billion yuan, with innovative drugs contributing 16.342 billion yuan; non-oncology products, while still under 20 percent of the mix, grew 73.36 percent year over year.

In August 2025, the company established a Biopharmaceuticals Business Unit led by Shiwen Huo to develop non-oncology franchises, with metabolic and cardiovascular disease as priority areas. Hengrui has said it expects 53 innovative products to reach approval between 2026 and 2028, spanning oncology, metabolism, cardiovascular, immunology, and respiratory indications.

What the Drug Is

Shudi insulin is described by the company as a long-acting basal insulin analog with a half-life of approximately 21 hours and steady-state glucose-lowering effects sustained beyond 42 hours, allowing once-daily subcutaneous injection. Hengrui has reported an R&D investment of roughly 544 million yuan for the program, which spans work in type 2 diabetes.

Industry analysts in China have described the product as a candidate “Me-better” relative to insulin glargine (Lantus), given the reported hypoglycemia profile, though no head-to-head data against insulin degludec (Tresiba) have been disclosed.

Phase 3 Evidence, With Caveats

Two pivotal Phase 3 trials in type 2 diabetes support the approval:

INS068-301, led by Professor Xiaoying Li of Fudan University’s Zhongshan Hospital, enrolled patients whose disease was inadequately controlled on basal insulin and ran for 26 weeks. Hengrui has reported that shudi insulin achieved HbA1c reductions comparable to insulin glargine, with a 35 percent reduction in nocturnal hypoglycemia.

INS068-302, led by Professor Linong Ji of Peking University People’s Hospital, enrolled patients whose disease was inadequately controlled on oral antidiabetic drugs and ran for 52 weeks. Hengrui has reported a 20 percent reduction in overall hypoglycemia and a 35 percent reduction in nocturnal hypoglycemia versus the comparator.

The figures cited above reflect company and conference presentations rather than published peer-reviewed manuscripts. Hypoglycemia comparisons in basal insulin trials are highly dependent on titration protocols and glycemic targets; without full publication, the magnitudes cited should be treated as preliminary.

Why the Approval Matters Beyond Insulin

For Hengrui executives, the approval carries strategic weight beyond a single product. Three implications stand out:

Capability validation. Shudi insulin gives Hengrui its first complete demonstration of taking a non-oncology biologic from discovery through NMPA approval, an expansion that required building metabolic-disease expertise inside a historically oncology-focused organization.

A regulatory bridge. Single-agent data are widely viewed as the clinical evidence base for HR17031, a fixed-dose combination of shudi insulin and a proprietary GLP-1 receptor agonist. Hengrui filed that application with the NMPA in March 2026; an approval decision is pending.

A portfolio anchor. The long-acting insulin platform is intended to pair with Hengrui’s earlier SGLT2 inhibitor hengligliptin and DPP-IV inhibitor ruigliptin, the triple-combination product HR20031 (already approved), and a deeper pipeline that includes HRS9531 (a GLP-1/GIP dual agonist), HRS-7535 (an oral small-molecule GLP-1 agonist), and HRS4729 (a triple-target agonist in early study).

HR17031 Data at ADA 2026

At the 2026 American Diabetes Association (ADA) Scientific Sessions, Hengrui presented data on HR17031 indicating, versus insulin glargine, greater HbA1c reduction, higher rates of combined glycemic targets, weight reduction or weight neutrality, lower total insulin dose requirements, and lower hypoglycemia risk. The detailed dataset has not yet appeared in a peer-reviewed publication, and the figures should be read as company-reported interim findings rather than established results.

A Squeezed but Recovering Insulin Market

China’s insulin market has been reshaped by successive national procurements. The first insulin procurement in 2021 cut average prices by 48 percent, and a 2024 follow-on round cut prices by an additional 3.8 percentage points. Domestic firms, including Gan & Lee Pharmaceuticals and Tonghua Dongbao, gained share that had previously belonged to Novo Nordisk, Sanofi, and Eli Lilly; their combined share has moved from roughly 70 percent to about 45 percent, according to industry analyses cited by Chinese investment platform Eastmoney.

After two consecutive years of decline, the Chinese insulin market recovered to 22.3 billion yuan in 2024, according to Eastmoney and EvaluatePharma figures cited in industry coverage. Novo Nordisk has reported 2024 China insulin sales of approximately 9.76 billion Danish kroner (about 1.41 billion U.S. dollars).

Globally, sales of insulin degludec (Tresiba) and insulin glargine U300 (Toujeo) together reached roughly 3.345 billion U.S. dollars in 2025, according to EvaluatePharma figures cited in industry coverage.

Open Questions

Several variables will shape how shudi insulin performs once it reaches hospitals, retail pharmacies, and reimbursement negotiations:

No head-to-head data against insulin degludec have been disclosed, complicating direct comparison with the global long-acting standard.

The hypoglycemia-reduction percentages cited reflect company and conference reporting rather than peer-reviewed manuscripts to date.

Hengrui’s commercial and medical-affairs operations have historically focused on oncology; success in endocrinology, primary care, and chronic-disease management will depend on rebuilding academic relationships with hospital endocrinology departments and on reframing patient-support services.

Pricing within China’s National Reimbursement Drug List and any future volume-based procurement remains to be negotiated.

For Hengrui, executives have framed shudi insulin as a credential rather than a standalone franchise: proof that the company can develop, register, and commercialize a non-oncology biologic in China, and a foundation for the wider metabolic portfolio to follow.

0
0
Loading